Nuevocor
PrivateLast Round
Series B
May 6, 2025
Total Funding Raised
$69M
Company Overview
Nuevocor is a Singapore-headquartered, IND-stage biotechnology company focused on developing gene therapies for cardiomyopathies, which are diseases of the heart muscle. The company's primary focus is on conditions driven by aberrant mechanobiology, the way cells sense and respond to physical forces. Its lead candidate, NVC-001, is an AAV-based gene therapy for treating LMNA-related dilated cardiomyopathy (LMNA DCM), a severe and aggressive form of the disease. Founded in 2020, the company has raised significant venture funding, including a US$45 million Series B round in May 2025, to advance its therapies into clinical trials in the US and Europe. Nuevocor has offices in Singapore and the United States and is expanding its presence to Europe.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuevocor Comps
Public and private peers based on sector, stage, and business model.
Nuevocor Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 6, 2025 | ||||
| Series A | Jun 18, 2021 |
Key People
Founding team and executive leadership
Nuevocor Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Xora Innovation | Series B, Series A |
| SEEDS Capital | Series B |
| Highlight Capital | Series B |
| ClavystBio | Series B |
| EDBI | Series B, Series A |
| Angelini Ventures | Series B |
| EVX Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
First-in-human study of NVC-001 for LMNA-associated DCM to begin.
- Apr 28, 2026
Dr. Shah appointed to lead global clinical development and medical affairs.
Nuevocor Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nuevocor's valuation, stock price, and market status.
